Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience

Radiology

Volumn 207, Issue 3, 1998, Pages 799-808

  Bellin, Marie France ^a   Roy, Catherine ^b   Kinkel, Karen ^c   Thoumas, Denis ^d   Zaim, Souhil ^a   Vanel, Daniel ^c   Tuchmann, Christine ^b   Richard, François ^a   Jacqmin, Didier ^b   Delcourt, Annick ^a   Challier, Emmanuel ^a   Lebret, Thierry ^a   Cluzel, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Genitourinary system, neoplasms; Lymphatic system, MR, 99.12943; Lymphatic system, neoplasms, 99.831; Magnetic resonance (MR), contrast enhancement, 99.12943; Pelvic organs, neoplasms, 80.32

Indexed keywords

ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMAGE ANALYSIS; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; LYMPHOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UROGENITAL TRACT TUMOR;

EID: 0031841323     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.207.3.9609907     Document Type: Article

References (38)

1. Paul DB, Loening SA, Narayana AS, Culp DA. Morbidity from pelvic lymphadenectomy in staging of the prostate. J Urol 1983; 129:1141-1144.
2. Parra RO, Andrus C, Bouillier J. Staging laparoscopic pelvic lymph node dissection: comparison of results with open pelvic lymphadenectomy. J Urol 1992; 147:875-878.
3. Hermansen DK, Whitmore WF Jr. Frozen section lymph node analysis in pelvic lymphadenectomy for prostate cancer. J Urol 1988; 139:1073-1074.
4. Epstein JI, Oesterling JE, Eggleston JC, Walsh PC. Frozen section detection of lymph node metastases in prostatic carcinoma: accuracy in grossly uninvolved pelvic lymphadenectomy specimens. J Urol 1986; 136:1234-1237.
5. Davis GL. Sensitivity of frozen section examination of pelvic lymph node for metastatic prostate carcinoma. Cancer 1995; 76:661-668.
6. Oyen RH, Van Poppel HP, Ameye FE, Van de Voorde WA, Baert AL, Baert LV. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 1994; 190:315-322.
7. Dooms GC, Hricak H, Crooks LE, Higgins CB. Magnetic resonance imaging of the lymph nodes: comparison with CT. Radiology 1984; 153:719-728.
8. Lee JKT, Heiken JP, Ling D, et al. Magnetic resonance imaging of abdominal and pelvic lymphadenopathy. Radiology 1984; 153:181-188.
9. Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. Radiology 1994; 190:807-811.
10. Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA, Ruijs SJH. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence. AJR 1996; 167:1503-1507.
11. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990; 175:494-498.
12. Tanoura T, Bernas M, Darkazanli A, et al. MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. AJR 1992; 159:875-881.
13. Guimaraes R, Clement O, Bittoun J, Carnot F, Frija G. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR 1994; 162:201-207.
14. Lee AS, Weissleder R, Brady TJ, Wittenberg J. Lymph nodes: microstructural anatomy at MR imaging. Radiology 1991; 178:519-522.
15. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175:489-493.
16. Hudgins PA, Anzai Y, Christino A, Morris M, McLachlan S. Dextran-coated superparamagnetic iron oxide MR contrast agent (Combidex) for imaging cervical lymph nodes: optimal dose, time of imaging, and pulse sequence (abstr). Proceedings of the American Society of Neuroradiology, Oak Brook, Ill: American Society of Neuroradiology, 1996; 247.
17. McLachlan S, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. JMRI 1994; 4:301-307.
18. Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin RB. Dextran-coated superparamagnetic iron oxide: an MR contrast agent for assessing lymph nodes in the head and neck. AJNR 1994; 15:87-94.
19. Anzai Y, Blackwell KE, Hirschowitz SL, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994; 192:709-715.
20. Anzai Y, Prince MR. Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer. JMRI 1997; 7:75-81.
21. Harisinghani MG, Saini S, Slater GJ, Schnall MD, Rifkin MD. MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations. JMRI 1997; 7:161-163.
22. Vassallo P, Matei C, Heston WDW, McLachlan S, Koutcher JA, Castellino RA. AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology 1994; 193:501-506.
23. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3:32-35.
24. Loening SA, Schmidt JD, Brown RC, Hawtrey CE, Fallon B, Culp DA. A comparison between lymphangiography and pelvic node dissection in the staging of prostatic cancer. J Urol 1977; 117:752-756.
25. Kim SH, Choi BI, Lee HP, et al. Uterine cervical carcinoma: comparison of CT and MR findings. Radiology 1990; 175:45-51.
26. Hricak H, Dooms GC, Jeffrey RB, et al. Prostate carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987; 102:331-336.
27. Dooms GC, Hricak H, Mosely MR, Foottles K, Fisher MR, Higgins CB. Characterization of lymphadenopathy by magnetic relaxation times: preliminary results. Radiology 1985; 155:691-697.
28. McClennan BL, Deyoe LA. The imaging evaluation of renal cell carcinoma: diagnosis and staging. Radiol Clin North Am 1994; 32: 55-69.
29. Vinnicombe SJ, Norman AR, Nicolson V, Husband JE. Normal pelvic lymph nodes: evaluation by CT scanning after bipedal lymphangiography. Radiology 1995; 194:349-355.
30. Levine MS, Arger PH, Coleman BG, Muihern CB, Pollack HM, Wein AJ. Detecting lymphatic metastases from prostatic carcinoma: superiority of CT. AJR 1981; 197:207-211.
31. Platt JF, Bree RL, Schwab RE. The accuracy of CT in the staging of carcinoma of the prostate. AJR 1987; 149:315-318.
32. Chagnon S, Cochand-Priollet B, Gzaeil M, et al. Pelvic cancers: staging of 139 cases with lymphography and fine-needle aspiration biopsy. Radiology 1989; 173:103-106.
33. Nagano T, Nakai Y, Taniguchi F, et al. Diagnosis of paraaortic and pelvic lymph node metastasis of gynecologic malignant tumors by ultrasound-guided percutaneous fine-needle aspiration biopsy. Cancer 1991; 68: 2571-2574.
34. Gothlin JH, Hoiem L. Percutaneous fine-needle biopsy of radiographically normal lymph nodes in the staging of prostatic carcinoma. Radiology 1981; 141:351-354.
35. Chambon C, Clement O, Le Blanche A, Schouman-Claeys E, Frija G. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging 1993; 11:509-519.
36. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986; 31:288-305.
37. Taupitz M, Wagner S, Hamm B, Binder A, Pfefferer D. Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits. AJR 1993; 161:193-200.
38. Bellin MF, Zaim S, Auberton E, et al. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 1994; 193:657-663.